drugset / Trial / NCT05865028

A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia

NCT05865028 ↗

Phase 2 Recruiting 32 enrolled Elizabeth J Franzmann Aveta Biomics, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to assess whether APG-157 can reduce the tumor size in participants with the study disease. Another purpose is to find out about the effects of APG-157 on certain tumor markers and oral rinses in participants with the study disease.

Timeline

Start
2023-05-24
Primary completion
2027-05-24
Completion
2028-05-24

Drugs

EvaluationDrugModalityDoseRoute
Subject APG-157 Unknown 200 mg Oral